The heavily scrutinized 340B Drug Pricing Program is back in the spotlight as the Trump administration targets drug costs in a recent Executive Order.
The 340B Drug Pricing Program has received a lot of attention in recent years. In 2018, the Centers for Medicare & Medicaid Services sought to reduce reimbursement to participating provider organizations for 340B drugs. However, those new rates were rejected by the Supreme Court last year.
Now, a recent Executive Order has revived attention on the program that was establised in 1992 with the intention of improving care for low-income and vulnerable patient populations.
Check out the infographic below, or read the full HealthLeaders coverage here.
Luke Gale is the revenue cycle editor for HealthLeaders.
KEY TAKEAWAYS
An Executive Order issued by the Trump administration aiming to rein in drug costs has significant implications for the 340B Drug Pricing Program.
In addition to creating a pathway to reduce Medicare reimbursement for 340B drugs, the order also requires participating provider organizations to make insulin and injectable epinephrine available to patients at or below the discounted prices that they pay.